BLRX earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.36. Updated 2026-07-23.
BioLineRx (BLRX) Research Hub
BioLineRx (BLRX) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.51 USD (-1.57%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.36, market cap 0.01B. This hub links to the full technical, earnings and options research available for BLRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 2.51 USD (-1.57%) |
| 52-week range | 2.5 USD – 3.49 USD |
| Trend regime | Range |
| 14-day RSI | 42.4 (Bearish) |
| Trailing P/E | -1.36 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for BLRX
Covered Call on BLRX: how it works, illustrative setup around the real 2.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BLRX: how it works, illustrative setup around the real 2.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BLRX: how it works, illustrative setup around the real 2.51 USD price, max profit/loss, breakeven and when to use it. Educational.
BLRX technical analysis: range, last 2.51 USD, RSI 42.4, 52w range 2.5 USD–3.49 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BLRX in?
BioLineRx (BLRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is BLRX in an uptrend or downtrend?
As of 2026-09-11, BLRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BLRX's trailing P/E ratio?
BLRX's trailing P/E is -1.36, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does BLRX next report earnings?
BLRX is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.15 USD.